Swedish medical equipment manufacturer C-RAD AB (STO:CRAD-B) and SeeTreat Pty Ltd, a developer of adaptive decision support radiotherapy (ART) software, announced on Friday that they have formed a partnership aimed at developing more connected and patient-centric radiotherapy workflows.

The collaboration combines C-RAD's Catalyst+ HD platform, which supports patient setup and real-time motion monitoring, with SeeTreat's ART.1 software for radiotherapy treatment planning. This integrated approach is designed to support the full radiotherapy session, from patient positioning through treatment plan assessment.

C-RAD and SeeTreat said the partnership addresses growing demand for radiotherapy workflows that improve precision, speed, safety and personalisation. The technologies are intended to help clinical teams make faster and more informed treatment decisions across both major cancer centres and smaller community clinics.

The partners will jointly explore clinical and product development opportunities, with further details expected later in 2026.